Peptisource

Tesamoreli,Ipamorelin 10/3(Blend)

As a synthetic growth hormone-releasing hormone (GHRH) analog, Tesamoreli demonstrates significant clinical value in the management of specific diseases. Its core therapeutic positioning is to intervene in the abnormal accumulation of abdominal fat in HIV-infected individuals caused by long-term antiretroviral therapy. This drug highly mimics the molecular action mode of endogenous GHRH, binds to the specific receptors on the surface of growth hormone cells in the anterior pituitary gland, activates the G protein-coupled signaling pathway, and then induces the pulsatile release of growth hormone (GH) from the anterior pituitary gland. With the continuous increase of GH concentration in the circulatory system, the synthesis process of insulin-like growth factor-I (IGF-I) in the liver and peripheral tissues is significantly activated. This key growth factor regulates the energy metabolism network of adipocytes - including enhancing the activity of lipolytic enzymes to promote visceral fat breakdown and inhibiting the expression of fatty acid synthase to reduce fat deposition - ultimately achieving the reconstruction of abnormal fat distribution and the reduction of abdominal fat load.

Spec: Blend
Packaging: 1kits（10Vials）
$220USD
1

▎Tesamoreli


As a synthetic growth hormone-releasing hormone (GHRH) analog, Tesamoreli demonstrates significant clinical value in the management of specific diseases. Its core therapeutic positioning is to intervene in the abnormal accumulation of abdominal fat in HIV-infected individuals caused by long-term antiretroviral therapy. This drug highly mimics the molecular action mode of endogenous GHRH, binds to the specific receptors on the surface of growth hormone cells in the anterior pituitary gland, activates the G protein-coupled signaling pathway, and then induces the pulsatile release of growth hormone (GH) from the anterior pituitary gland. With the continuous increase of GH concentration in the circulatory system, the synthesis process of insulin-like growth factor-I (IGF-I) in the liver and peripheral tissues is significantly activated. This key growth factor regulates the energy metabolism network of adipocytes - including enhancing the activity of lipolytic enzymes to promote visceral fat breakdown and inhibiting the expression of fatty acid synthase to reduce fat deposition - ultimately achieving the reconstruction of abnormal fat distribution and the reduction of abdominal fat load.


In addition to the fat-reducing effect on the target organs, the pharmacological effects of Tesamoreli generate multiple physiological benefits through the systemic regulation of the GH-IGF-I axis: at the level of body composition optimization, it promotes the amino acid uptake of skeletal muscle cells and activates the myofiber regeneration process mediated by satellite cells, maintaining or increasing the proportion of lean body mass, and thus having a positive regulatory effect on muscle strength. This effect is closely related to the enhanced protein synthesis and inhibited protein breakdown mediated by growth hormone; in the field of bone metabolism, this drug has a protective effect on bone mineral density through a dual mechanism of promoting the differentiation and maturation of osteoblasts and inhibiting the activity of osteoclasts, especially providing a potential intervention approach for the prevention of bone loss associated with chronic diseases. The above mechanisms of action indicate that Tesamoreli is not limited to the improvement of local fat accumulation but rather achieves the integrated regulation of the physiological functions of multiple systems throughout the body by targeting the endocrine metabolic axis.